MedTrace Logo

the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

NCT05497076 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2022-08-11

No results posted yet for this study

Summary

Efficacy and safety of Dalpiciclib combined with third-generation EGFR-TKI in patients with advanced EGFR-mutated non-small cell lung cancer with meningeal metastasis after third-generation TKI and platinum-containing chemotherapy

Conditions

  • Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology
  • The TNM (8th) Phase is IV
  • With EGFR Mutations
  • Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment
  • Male or Female
  • The Age of 18 Years Old or More
  • ECOG PS 0 to 2 Points

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-01-01
Completion
2024-07-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05497076 on ClinicalTrials.gov